Project description
Proactive cancer monitoring versus surgery
The original PRISAR consortium implemented an innovative approach using imaging technologies and hybrid fluorescence/radionuclide probes for surgical intervention in cancer treatment. That project resulted in the development of a hybrid probe for image-guided surgery as well as a variety of additional tools and instruments. Now, the EU-funded PRISAR2 project aims to continue this effort by developing new industrial monitoring technologies for the surveillance of cancer. This innovative imaging-based platform will increase the surveillance window to allow for optimal selection of treatment options over time, possibly avoiding surgery. The 'watch and wait' strategies will enable better study of the cancer's progression so that any risks to the patient can be minimised leading to a better clinical outcome.
Objective
From 2016 -2019, the “first” PRISAR consortium implemented the first Dutch RISE project of H2020 to investigate the use of imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. This PRISAR project provided a career-enabling human resource plethora of inter-disciplinary and inter-sectoral secondments, which resulted in the development, of not only a hybrid probe for image-guided surgery, but also a variety of tools and instruments. We now propose a new project, PRISAR2, to implement the next logical phase of this work, which is to clinically translate new and innovative monitoring technologies from industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new ‘watch and wait’ strategies to study the behaviour of the cancer so that any risks can be minimized. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximize the benefits of an active monitoring policy for both the patient and the healthcare system. When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Here, however, we aim to (a) develop new monitoring technologies from industry so that the surveillance window can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch and wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a better clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this new concept as standard of care and to maximise the benefits of an active monitoring policy.
Fields of science
Keywords
Programme(s)
Coordinator
Participation ended
2573 HT 's-Gravenhage (Den Haag)
Netherlands
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participants (24)
62032 Camerino
See on map
67659 Kaiserslautern
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
67081 Strasbourg
See on map
84036 Landshut
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
L69 7ZX Liverpool
See on map
37075 Goettingen
See on map
B72 1SD Sutton Coldfield
See on map
960 01 Zvolen
See on map
34000 Montpellier
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
80138 Napoli
See on map
S10 2TN Sheffield
See on map
3500 Vaerlose
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
NW10 7EW London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
95488 Eckersdorf
See on map
00074 Nemi
See on map
2820 266 Charneca De Caparica
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
2333 ZA Leiden
See on map
00040 Nemi
See on map
3015 GD Rotterdam
See on map
Participation ended
00074 Nemi
See on map
40225 Dusseldorf
See on map
EH8 9YL Edinburgh
See on map
2333 CG Leiden
See on map
1114 AB Amsterdam
See on map